iSpecimen Inc

iSpecimen Inc

ISPC · NASDAQ · Healthcare / Diagnostics & Research

0.6587USD-0.04 (-5.43%)

Price History

Full chart

Market Stats

Previous Close0.6965
Open0.69
Day Range0.63 – 0.69
52-Week Range1.18 – 52.80
Volume113.25K
Market Cap3.17M
P/E (TTM)0.00
Forward P/E0.00
EPS-50.48
Dividend Yield0.00%
Beta1.62
50-Day Avg1.82
200-Day Avg6.65

About

iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. The company's marketplace offers human biospecimens, including biofluids, such as whole blood, plasma, serum, urine, saliva, sputum, nasopharyngeal material, and cerebral spinal fluid; solid tissue comprising fresh, fixed, and cryopreserved tissue, as well as formalin-fixed paraffin embedded blocks, slides, and curls; and hematopoietic stem and immune cells, including bone marrow, cord blood, whole blood, or sub-components of these tissues, such as peripheral blood mononuclear cells and other isolated cell types. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Woburn, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMr. Shahin Behroyan
  • Employees7
  • Headquarters8 Cabot Road, Woburn, MA, United States, 01801, USA
  • Websitehttps://ispecimen.com

Leadership

  • Mr. Yuying LiangChief Financial Officer · b. 1990
  • Mr. Shahin BehroyanChief Executive Officer · b. 1987

Financials

Income Statement

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.39M4.30M8.18M11.14M10.40M9.93M9.29M1.93M
Growth (%)--2.20%+90.40%+36.06%-6.58%-4.56%-6.42%-79.24%
Cost of Revenue2.36M2.13M3.59M5.25M4.76M4.82M5.30M1.90M
Gross Profit2.03M2.17M4.60M5.89M5.65M5.11M3.99M24.11K
Gross Margin46.24%50.49%56.19%52.86%54.27%51.45%42.93%1.25%
Operating Expense5.39M6.05M7.01M11.81M15.83M16.28M16.72M9.00M
Operating Income-3.36M-3.88M-2.41M-5.93M-10.19M-11.17M-12.73M-8.98M
Operating Margin-76.37%-90.27%-29.40%-53.21%-97.92%-112.50%-136.99%-465.42%
EBITDA-3.79M-2.52M-1.74M-5.86M-8.80M-8.80M-10.38M-8.75M
EBITDA Margin-86.24%-58.73%-21.21%-52.58%-84.61%-88.67%-111.69%-453.43%
Net Income-5.35M-4.73M-4.65M-8.96M-10.25M-11.10M-12.50M-10.49M
Net Income Margin-121.67%-109.97%-56.84%-80.48%-98.50%-111.80%-134.51%-543.68%
R&D1.21M993.33K1.47M1.84M2.66M3.57M3.53M2.16M
R&D as % of Total Revenue27.53%23.11%17.90%16.51%25.54%35.93%38.00%111.97%
Interest Expense1.21M1.72M2.10M2.10M238.96K230.78K220.07K1.95K
Interest Expense % of Total Revenue27.65%40.12%25.62%18.88%2.30%2.32%2.37%0.10%

Balance Sheet

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.04M4.21M6.21M35.72M24.62M15.82M9.35M9.53M
Total Liabilities22.47M26.93M33.49M5.93M4.31M6.08M6.04M6.44M
Total Equity-18.42M-22.72M-27.28M29.79M20.31M9.74M3.31M3.09M
Cash1.13M53.89K695.91K27.74M15.31M2.34M1.88M6.88M
Total Debt6.97M10.59M12.77M3.42M185.85K196.24K312.17K268.80K
Net Debt5.84M10.54M12.07M-24.32M-15.12M-2.15M-1.57M-6.61M

Cash Flow

Currency: USD2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-2.68M-2.68M-288.38K-10.67M-5.82M-5.81M-8.26M-4.24M
Investing Cash Flow-1.03M-1.48M-1.10M-1.04M-3.19M-7.23M1.98M-1.00M
Financing Cash Flow3.52M3.08M2.03M38.75M-3.42M70.89K5.82M10.24M
Capital Expenditure1.03M1.48M1.10M1.04M3.19M4.74M56.55K454
Free Cash Flow-3.71M-4.16M-1.39M-11.71M-9.01M-10.55M-8.30M-4.24M
FCF to OCF138.25%155.05%482.35%109.73%154.85%181.70%100.38%100.01%

Earnings

Report DateSep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Jan 20, 2021Jun 17, 2021Aug 10, 2021Nov 4, 2021Feb 17, 2022May 10, 2022Aug 4, 2022Nov 8, 2022Mar 14, 2023May 4, 2023Aug 2, 2023Nov 2, 2023Mar 13, 2024May 7, 2024Aug 6, 2024Oct 31, 2024May 19, 2025Aug 14, 2025Nov 17, 2025Mar 12, 2026May 29, 2026Aug 14, 2026Nov 16, 2026
EPS Estimate0.000.000.000.000.000.000.000.000.00--168.00-202.67-220.00-272.00-0.37-256.00-240.00-280.00-0.24-216.00-224.00-0.29-0.31-0.00----
EPS Actual-2.25-1.44-1.75-0.19-1.33-1.70-0.19-0.25-0.21-0.22-136.00-216.00-240.00-280.00-0.24-216.00-312.00-184.00-0.32-256.00-152.00-2.10-0.71-0.42-0.48-23.59-6.66-0.98-
Surprise----------19.05%-6.58%-9.09%-2.94%35.14%15.63%-30.00%34.29%-33.33%-18.52%32.14%-622.55%-129.03%------
Timing-------After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market--------

Key Statistics & Ratios

Market Cap3.17M
Enterprise Value-1.13M
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.81
Price / Book1.76
EPS-50.48
Book Value1.14
Revenue (TTM)466.30K
Gross Profit (TTM)-504.83K
EBITDA-9.28M
Profit Margin0.00%
Operating Margin-897.06%
Return on Equity-968.47%
Return on Assets-87.69%
Shares Outstanding2.52M
Shares Float2.52M
Beta1.62
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 1 analystsTarget 3.00
  • Strong Buy
    1

Ownership Breakdown

Institutions
2.58%
Insiders
0.04%
Retail / Other
97.38%

Top Institutional Holders

  • IFP Advisors, LLC
    8.20K0.33%
  • Geode Capital Management, LLC
    313.10K0.31%
  • Jane Street Group LLC
    55.63K0.06%
  • UBS Group AG
    53.74K0.05%
  • Tower Research Capital LLC
    6.65K0.01%
  • BlackRock Inc
    2.83K0.00%
  • SBI Securities Co Ltd
    190.00%
  • Susquehanna International Group, LLP
    00.00%
  • Jump Financial LLC
    00.00%
  • Sachetta LLC
    00.00%
  • Bank of America Corp
    00.00%
  • Citadel Advisors Llc
    00.00%

Top Fund Holders

  • Fidelity Extended Market Index
    7.33K0.29%

Stock Splits

  • Apr 28, 20261:40
  • Sep 16, 20241:20